Clinical Trials on Stage IIC Melanoma (Locally Advanced)

Total 4073 results

National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
First People's Hospital of Hangzhou
Hangzhou Cancer Hospital

Recruiting

A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Non Small Cell Lung Cancer | EGFR Activating Mutation | Stage III NSCLC

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

Nonsmall Cell Lung Cancer Stage III | Pneumonitis

United States
National Cancer Institute (NCI)

Terminated

O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma

Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma | Stage I Cutaneous T-cell Non-Hodgkin Lymphoma | Stage II Cutaneous T-cell Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Recurrent Fallopian Tube Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Recurrent Platinum-Resistant Ovarian Carcinoma | Metastatic Fallopian Tube Carcinoma | Metastatic Primary... and other conditions

United States
AP Biosciences Inc.

Not yet recruiting

A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies (APT-CUBE)

Esophageal Squamous Cell Carcinoma (ESCC) | Locally Advanced or Metastatic Solid Tumors | Non Small Cell Lung Cancer (NSCLC) | Head and Neck Squamous Cell Carcinoma (HNSCC)
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Endometrial Adenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Gastrointestinal Complication and other conditions

United States
National Cancer Institute (NCI)

Terminated

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Previously Treated Myelodysplastic... and other conditions

United States
Universitätsklinikum Hamburg-Eppendorf

Terminated

Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer (BYPAPA)

Advanced Cancer | Jaundice | Pancreatic Cancer Non-resectable | Local Tumor Spread | Metastasized

Germany
Regeneron Pharmaceuticals

Not yet recruiting

A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies

Melanoma | Advanced Solid Tumors | Clear-Cell Renal-Cell Carcinoma (ccRCC)
MacroGenics

Terminated

MGC018 With or Without MGA012 in Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Metastatic Castrate Resistant Prostate Cancer | Advanced Solid Tumor, Adult

Spain, United States, Australia, Poland
OncoResponse, Inc.

Recruiting

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Melanoma | Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Solid Tumor | Leiomyosarcoma | Head and Neck Squamous Cell Carcinoma | Liposarcoma | Malignant Neoplasm | Tumor, Solid

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Cancer and Blood Pressure Management, CARISMA Study

Metastatic Renal Cell Carcinoma | Chronic Kidney Disease | Stage IV Renal Cell Cancer AJCC v8 | Cardiovascular Disorder | Metastatic Thyroid Gland Medullary Carcinoma | Stage IV Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8 | Stage IVB Thyroid Gland... and other conditions

United States
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Fallopian Tube Cancer | Stage IV Ovarian Epithelial Cancer | Primary Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer | Stage III Ovarian Epithelial Cancer

United States
Taiho Oncology, Inc.

Recruiting

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Pancreatic Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Cancer | Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer | Siewert Type 1 GEJ Cancer

United States, Spain, Germany, France
Intergroupe Francophone de Cancerologie Thoracique

Completed

Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2)

Non Small Cell Lung Cancer Metastatic | HER2 Gene Mutation | Non Small Cell Lung Cancer Stage III

France
Attikon Hospital

Completed

Renal Cell Carcinoma and Stage IV Inferior Vena Cava Thrombus: Resection Without Thoracotomy

Renal Cell Carcinoma Stage III

Greece
National Cancer Institute (NCI)

Completed

2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors

Stage III Multiple Myeloma | Unspecified Adult Solid Tumor, Protocol Specific | Refractory Multiple Myeloma

United States
UMC Utrecht
The Netherlands Cancer Institute; Personal Genome Diagnostics (PGDx)

Recruiting

Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial (CrEATE)

Recurrence | Circulating Tumor DNA | Colon Cancer Stage II

Netherlands
National Taiwan University Hospital
Samsung Medical Center; Chang Gung Memorial Hospital; Tokyo University

Not yet recruiting

Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of Recurrence

FIGO Stage IC2 to II Ovarian Clear Cell Carcinoma
Cedars-Sinai Medical Center

Terminated

Radiogenomics of Muscle Invasive Bladder Cancer

Bladder Cancer Stage II

United States
National Taiwan University Hospital

Unknown

A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer

Stage II Colon Cancer | MSI-L/MSS

Taiwan
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Obesity | Fatigue | Stage I Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Neurotoxicity Syndrome

United States, Korea, Republic of
Sunnybrook Health Sciences Centre
GlaxoSmithKline

Recruiting

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

Ovarian Cancer | Stage IV Ovarian Cancer | High Grade Ovarian Serous Adenocarcinoma | Stage III Ovarian Cancer

Canada
University of California, San Francisco
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Clear Cell Renal Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

Ovarian Cancer | Fallopian Tube Cancer | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
Centre Francois Baclesse

Completed

Search for Predictors of Therapeutic Response in Ovarian Carcinoma (miRSa)

Fallopian Tube Cancer | Carcinoma of the Ovary | Peritoneal Serous-type Advanced Stage

France
Heidelberg University
University Hospital Heidelberg

Terminated

TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors (TPF-C-HIT)

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN): Oro-, Hypopharyngeal and Laryngeal Cancer

Germany
The First Hospital of Jilin University

Not yet recruiting

To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer
Fred Hutchinson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

Anal Canal Cloacogenic Carcinoma | Metastatic Anal Squamous Cell Carcinoma | Recurrent Anal Squamous Cell Carcinoma | Stage III Anal Cancer AJCC v8 | Stage IV Anal Cancer AJCC v8 | Unresectable Anal Squamous Cell Carcinoma | Anal Basaloid Squamous Cell Carcinoma

United States
OHSU Knight Cancer Institute
Astellas Pharma US, Inc.; Oregon Health and Science University

Active, not recruiting

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Soft Tissues | Recurrent Prostate Carcinoma | Metastatic Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage IV Prostate Adenocarcinoma AJCC v7

United States
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Unknown

NK Cells in Cord Blood Transplantation

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia and other conditions

United States
University of California, Irvine
Patient-Centered Outcomes Research Institute

Completed

Ovarian Cancer Patient-Centered Decision Aid (PCOA)

Stage III Ovarian Cancer

United States
Agenus Inc.

Recruiting

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Melanoma | Ovarian Cancer | Prostate Cancer | Non-small-cell Lung Cancer | Endometrial Cancer | Advanced Cancer | Angiosarcoma | Fibrolamellar Carcinoma | Colorectal Cancer Without Liver Metastases

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Oropharyngeal Squamous Cell Carcinoma | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

United States
Loren Mell, MD
Merck Sharp & Dohme LLC

Recruiting

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

Cancer | Head and Neck Squamous Cell Carcinoma | Oral Cancer | Tumor | Oropharynx Cancer | Cancer of Head and Neck | Oropharyngeal Cancer | Cancer, Advanced | Cancer, Metastatic | Tumor Metastasis | Tumor Recurrence | Tumor Neck | Oropharynx Cancer, Stage III | Oropharynx Cancer, Recurrent | Oropharynx Cancer, Metastatic

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

Human Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx | Stage IVB Squamous Cell Carcinoma of the Oropharynx

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer (OPTIMA)

Human Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IVA Squamous Cell Carcinoma of the Oropharynx | Stage IVB Squamous Cell Carcinoma of the Oropharynx

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer

United States
Clovis Oncology, Inc.

Terminated

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Small Cell Lung Cancer | Non-Small Cell Lung Cancer | NSCLC | Lung Cancer | Metastatic Lung Cancer | SCLC | Stage IV Lung Cancer | Advanced Lung Cancer | Squamous Non-Small Cell Lung Cancer

United States, Italy, Germany, France, Spain
University of Washington
National Institute of Nursing Research (NINR)

Completed

Improving Clinician Communication Skills (ICCS) (ICCS)

End Stage Liver Disease | Chronic Obstructive Pulmonary Disease (COPD) | Advanced Cancer | Congestive Heart Failure | Restrictive Lung Disease

United States
Infinity Pharmaceuticals, Inc.

Active, not recruiting

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Advanced Solid Tumors (Part A/B/C/D) | Non-small Cell Lung Cancer (Part E) | Melanoma (Part E) | Squamous Cell Cancer of the Head and Neck (Part E) | Triple Negative Breast Cancer (Part F) | Adrenocortical Carcinoma (Part G) | Mesothelioma (Part G) | High-circulating Myeloid-derived Suppressor Cells...

United States
Sarah Goldberg
Mirati Therapeutics Inc.

Terminated

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | Sitravatinib

United States
Wake Forest University Health Sciences

Withdrawn

Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body

Lung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma

Clinical Trials on Stage IIC Melanoma (Locally Advanced)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations